论文部分内容阅读
目的:探讨伊班膦酸钠注射液联合钙尔奇D片治疗老年性骨质疏松症的疗效及对患者血尿常规、肝肾功能及心电图的影响。方法:选择我院收治的72例老年骨质疏松症患者,采用随机数字表法将其分为观察组和对照组各36例,观察组给予伊班膦酸钠注射液联合钙尔奇D片进行治疗,对照组仅给予钙尔奇D片进行治疗,治疗时间为12个月,在治疗前,治疗后6个月及治疗后12个月时对比两组治疗效果及临床不良反应发生情况,并对两组患者的血尿常规、肝肾功能及心电图进行对比检查。结果:观察组在治疗6个月时BALP和TRAP-5b分别为(10.96±0.93)ug/L、(3.71±0.72)U/L,较治疗前和对照组均明显下降,比较差异均有统计学意义(P<0.05);观察组在治疗12个月时BALP和TRAP-5b分别为(10.91±0.81)ug/L、(3.73±0.65)U/L,较治疗前和对照组亦显著下降,比较差异均有统计学意义(P<0.05);对照组在治疗后6个月及12个月时,各检测指标统计值与治疗前比较,变化不大,比较差异均无统计学意义(P>0.05);两种患者在治疗前、6个月、12个月时血尿常规、肝肾功能及心电图之间无统计学差异(P>0.05);两组患者中均无明显严重的不良反应发生,不良反应发生情况比较差异无统计学意义(P>0.05)。结论:临床中联合应用伊班膦酸钠注射液和钙尔奇D片对老年性骨质疏松症进行治疗,可获得较为满意疗效,且对患者血尿常规、肝肾功能及心电图影响较小,不良反应发生率较低,病人耐受度较好,故值得在临床中应用。
Objective: To investigate the curative effect of ibandronate sodium injection combined with Calcium Acetate D on senile osteoporosis and its effect on blood routine, liver and kidney function and electrocardiogram in patients. Methods: Seventy-two elderly patients with osteoporosis admitted to our hospital were randomly divided into observation group (36 cases) and control group (36 cases). The observation group was given ibandronate sodium injection in combination with calcium- The control group was given only calcium galloch D tablets for treatment, the treatment time was 12 months before treatment, 6 months after treatment and 12 months after treatment when compared the two groups of treatment and clinical adverse reactions, And two groups of patients with hematuria routine, liver and kidney function and ECG comparison check. Results: The BALP and TRAP-5b in the observation group were (10.96 ± 0.93) ug / L and (3.71 ± 0.72) U / L respectively at 6 months after treatment, which were significantly lower than those before treatment and the control group (10.91 ± 0.81) ug / L and (3.73 ± 0.65) U / L respectively in the observation group at 12 months, which was significantly lower than that before treatment and in the control group , Respectively (all P <0.05). In the control group at 6 months and 12 months after treatment, there was no significant difference between the statistics of each test index and before treatment, with no significant difference (P> 0.05) P> 0.05). There was no significant difference in hematuria, liver and renal function and ECG between the two groups before treatment, 6 months and 12 months (P> 0.05). There was no significant difference between the two groups The reaction occurred, there was no significant difference in adverse reactions (P> 0.05). Conclusion: The clinical application of ibandronate sodium injection and Calcium Acetate D tablets in the treatment of senile osteoporosis can be obtained with satisfactory curative effect, and has little effect on the patients’ hematuria, liver and kidney function and electrocardiogram, The incidence of adverse reactions is lower, the patient tolerance is better, it is worth in clinical application.